

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

**Applicants:** Kathryn E. Lawlor, et al.      **Examiner:** Cherie M. Woodward

**Serial No:** 10/525,363      **Art Unit:** 1647

**Filed:** September 6, 2005      **Docket:** 18688

**For:** A METHOD FOR TREATMENT AND PROPHYLAXIS OF ARTHRITIS BY INHIBITING ACTIVITIES OF G-CSF AND/OR G-CSFR      **Dated:** February 19, 2010

**Confirmation No.:** 5197

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**

Sir:


In accordance with 37 C.F.R §§1.97 and 1.98, it is requested that the following references, which are also listed on the attached Form PTO-1449, be made of record in the above-identified case.

1. MIYAHARA, H. et al., "The Effects of Recombinant Human Granulocyte Colony-Stimulating Factor on Passive Collagen-Induced Arthritis Transferred with Anti-Type II Collagen Antibody" *Clinical Immunology and Immunopathology* (1993) pp. 69-76, Vol. 69(1);
2. "Arthritis and Rheumatism" *American College of Rheumatology* (1995) pp. S355, Vol. 38 (9 Supplement); and

**CERTIFICATION OF ELECTRONIC FILING**

I hereby certify that this correspondence is being deposited with the United States Patent and Trademark Office via Electronic Filing through the United States Patent and Trademark Office e-business website, on February 19, 2010.

Dated: February 19, 2010



Xiaochun Zhu

3. NAKASHIMA, H. et al., "Rheumatoid Arthritis Exacerbation by G-CSF treatment for Bucillamine-Induced Agranulocytosis" *Clinical Exp. Rheumatology* (1995) pp/ 677-679, Vol. 13(5).

The references listed above were cited in a Notice of Reasons for Rejection dated November 9, 2009 received from the Japanese Patent Office, issued in the corresponding Japanese application. Applicants are submitting copies of the above references, together with an English translation of the Notice of Reasons for Rejection. The relevance of the references is described in the Rejection.

Please note that the other two references cited in the Notice of Reasons for Rejection, namely, WO 95/21867 and Campbell et al. (2000), were previously submitted in Applicants Information Disclosure Statement dated November 19, 2005.

In compliance with the requirements of 37 C.F.R. §1.98(a)(3), as a concise statement of relevance, as it is presently understood by the individual designated in 37 C.F.R. §1.56(c) most knowledgeable about the content of the information, the undersigned attorney of record submits a translation of portions of a Notice of Reasons for Rejection by a foreign examiner in which the references were cited. The relevance to the pending U.S. patent application is that the references were cited in a foreign patent application on the same subject matter. However, no independent analysis of the references, the accuracy of the statement of the foreign examiner or the claims of the foreign application under the laws of that country or the United States relative to the subject matter claimed in the present application has been made; the present understanding of the contents thereof by the undersigned being based on the translation of the foreign examiner's comments submitted herewith.

Inasmuch as this Information Disclosure Statement is being submitted in accordance with the schedule set out in 37 C.F.R. §1.97(c), please charge the \$180.00 fee to deposit account no. 19-1013/SSMP.

Respectfully submitted,



Xiaochun Zhu  
Registration No. 56,311

Scully, Scott, Murphy & Presser, P.C.  
400 Garden City Plaza –Suite 300  
Garden City, New York 11530  
(516) 742-4343  
XZ:eh